BTIG Reaffirms Ocular Therapeutix (OCUL) at 'Buy' Amid Regeneron (REGN) Collaboration; Offers Commentary

October 14, 2016 11:58 AM EDT
Get Alerts OCUL Hot Sheet
Price: $8.09 --0%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade OCUL Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

BTIG affirms Ocular Therapeutix, Inc. (Nasdaq: OCUL) at Buy with a price target of $18 following its latest collaboration with Regeneron (Nasdaq: REGN).

Analyst Dane Leone noted the following on Friday:

  • Benefit of sustained-release VEGF depot. If successfully developed, the sustained-release depot could potentially reduce the dosing frequency substantially, thereby reducing treatment burden of anti-VEGF agents, as well as potentially extend patent protection.
  • Favorable terms. If REGN exercises the option, OCUL is entitled to receive $10M from REGN, milestone payments of up to $305M and high single-digit to low-to-mid teen-digit royalties on net product sales. OCUL will be responsible for the Phase I trial, while REGN will be responsible for all following clinical, regulatory and commercial costs. Management mentioned that there are additional formulary work and toxicity studies that need to be done before the program enters clinical trials (detailed timing not provided).
  • Encouraging preclinical data. The protein-based anti-VEGF depot and TKI depots were shown to have sustained release of the drugs for up to 6 months, inhibit vascular leakage and have a good in vivo tolerability profile (minimal inflammatory response).

For an analyst ratings summary and ratings history on Ocular Therapeutix click here. For more ratings news on Ocular Therapeutix click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment